NASDAQ:TRAW Traws Pharma (TRAW) Stock Price, News & Analysis $0.43 +0.02 (+4.88%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.40▼$0.4450-Day Range$0.35▼$0.6652-Week Range$0.33▼$1.10Volume28,345 shsAverage Volume103,485 shsMarket Capitalization$10.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsOptions ChainSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsOptions ChainSEC FilingsShort InterestTrends Get Traws Pharma alerts: Email Address Traws Pharma MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.72) to ($0.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.25 out of 5 starsMedical Sector920th out of 936 stocksPharmaceutical Preparations Industry429th out of 436 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Traws Pharma.Read more about Traws Pharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.19% of the float of Traws Pharma has been sold short.Short Interest Ratio / Days to CoverTraws Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldTraws Pharma does not currently pay a dividend.Dividend GrowthTraws Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRAW. Previous Next 2.6 News and Social Media Coverage News SentimentTraws Pharma has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Traws Pharma this week, compared to 3 articles on an average week.Search Interest3 people have searched for TRAW on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows3 people have added Traws Pharma to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Traws Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Traws Pharma is held by insiders.Percentage Held by InstitutionsOnly 7.95% of the stock of Traws Pharma is held by institutions.Read more about Traws Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Traws Pharma are expected to decrease in the coming year, from ($0.72) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Traws Pharma is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Traws Pharma is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTraws Pharma has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Traws Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About Traws PharmaTraws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for patients with check point inhibitor (CPI) resistant K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China; with SymBio Pharmaceuticals Limited for the development and commercialization of rigosertib in Japan and Korea; and Pint License Agreement to develop and commercialize any pharmaceutical product containing rigosertib in all uses of rigosertib in humans in Latin American countries. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Read More TRAW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRAW Stock News HeadlinesJuly 25 at 11:17 AM | uk.investing.comTraws Pharma Inc (TRAW)July 19, 2024 | finance.yahoo.com0T2.SG,0P0000ZC8L,0 (0T2.SG)See More Headlines Receive TRAW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Traws Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TRAW CUSIPN/A CIK1130598 Webwww.onconova.com Phone267-759-3680Fax267-759-3681Employees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,950,000.00 Net Margins-8,033.63% Pretax Margin-8,033.63% Return on Equity-144.95% Return on Assets-73.83% Debt Debt-to-Equity RatioN/A Current Ratio1.93 Quick Ratio1.93 Sales & Book Value Annual Sales$230,000.00 Price / Sales47.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book0.84Miscellaneous Outstanding Shares25,310,000Free Float24,472,000Market Cap$10.88 million OptionableOptionable Beta1.37 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Steven M. Fruchtman M.D. (Age 73)President & Chief Scientific Officer of Oncology Comp: $907.86kMr. Mark Patrick Guerin CPA (Age 55)Chief Financial Officer Comp: $629.27kDr. Iain D. Dukes DPHIL (Age 66)M.A., Ph.D., Executive Chairman Dr. Werner Cautreels Ph.D. (Age 72)CEO & Director Dr. Nikolay Savchuk Ph.D. (Age 55)COO & Director Dr. Victor Moyo M.D.Chief Medical OfficerRobert Redfield M.D.Acting Chief Medical OfficerCharles David Pauza Ph.D.Chief Scientific Officer of VirologyMore ExecutivesKey CompetitorsLexaria BioscienceNASDAQ:LEXXTempest TherapeuticsNASDAQ:TPSTProMIS NeurosciencesNASDAQ:PMNAcurx PharmaceuticalsNASDAQ:ACXPCue BiopharmaNASDAQ:CUEView All Competitors TRAW Stock Analysis - Frequently Asked Questions How have TRAW shares performed this year? Traws Pharma's stock was trading at $0.8081 at the beginning of the year. Since then, TRAW stock has decreased by 46.8% and is now trading at $0.43. View the best growth stocks for 2024 here. How were Traws Pharma's earnings last quarter? Traws Pharma, Inc. (NASDAQ:TRAW) issued its earnings results on Wednesday, May, 15th. The company reported ($0.24) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.24). The firm earned $0.06 million during the quarter, compared to analyst estimates of $0.06 million. Traws Pharma had a negative net margin of 8,033.63% and a negative trailing twelve-month return on equity of 144.95%. How do I buy shares of Traws Pharma? Shares of TRAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TRAW) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRAW Stock Alerts